---
id: 191
title: Malaria Chemoprophylaxis for Travelers
category: travel_medicine
subcategory: prevention
tags: [malaria, prophylaxis, atovaquone-proguanil, doxycycline, mefloquine, travel, chloroquine-resistance]
difficulty: medium
---

## Question

What are the malaria prophylaxis options? Use **"Atovaquone-Proguanil (Best Tolerability), Doxycycline (Cheap), Mefloquine (Weekly), Chloroquine (Rare)"** framework.

## Answer

### **Malaria Overview:**

**Transmission:** *Anopheles* mosquito (bites dusk-dawn)

**Species:** *P. falciparum* (most dangerous), *P. vivax*, *P. ovale*, *P. malariae*, *P. knowlesi*

**Resistance:** Chloroquine resistance widespread (except Central America, Caribbean, parts of Middle East)

### **Chemoprophylaxis Options:**

**Atovaquone-Proguanil (Malarone):**
- **Dose:** 1 tablet (250/100mg) PO daily
- **Timing:** Start **1-2 days before**, continue **daily during**, stop **7 days after** leaving endemic area
- **Advantages:** Short post-travel course (7 days), well-tolerated, causal prophylaxis (kills liver-stage parasites)
- **Disadvantages:** Expensive, daily dosing

**Doxycycline:**
- **Dose:** 100mg PO daily
- **Timing:** Start **1-2 days before**, continue **daily during**, stop **28 days after** leaving endemic area
- **Advantages:** Inexpensive, widely available
- **Disadvantages:** GI upset, photosensitivity, esophagitis (take with food/water), long post-travel course (28 days), contraindicated in pregnancy/children <8 years

**Mefloquine (Lariam):**
- **Dose:** 250mg PO weekly
- **Timing:** Start **≥2 weeks before** (loading period to assess tolerability), continue **weekly during**, stop **4 weeks after** leaving endemic area
- **Advantages:** Weekly dosing (convenient for long-term travelers)
- **Disadvantages:** Neuropsychiatric side effects (insomnia, anxiety, depression, vivid dreams, rare psychosis), contraindicated in seizure disorders/psychiatric illness, cardiac conduction abnormalities

**Chloroquine:**
- **Dose:** 500mg (base) PO weekly
- **Timing:** Start **1-2 weeks before**, continue **weekly during**, stop **4 weeks after** leaving endemic area
- **Indications:** **Chloroquine-sensitive areas ONLY** (Central America west of Panama Canal, Caribbean, parts of Middle East)
- **Advantages:** Safe in pregnancy, well-tolerated, inexpensive
- **Disadvantages:** Resistance widespread (NOT effective in most of sub-Saharan Africa, Asia, South America)

**Primaquine:**
- **Dose:** 30mg (base) PO daily
- **Timing:** Start **1-2 days before**, continue **daily during**, stop **7 days after** leaving endemic area
- **Advantages:** Effective against all species, short post-travel course (7 days), terminal prophylaxis (kills liver hypnozoites of *P. vivax/ovale*)
- **Disadvantages:** Requires **G6PD testing** before use (hemolysis in G6PD deficiency), not widely used for primary prophylaxis (more for terminal prophylaxis)
- **Use:** Alternative for short-term travelers, OR **terminal prophylaxis** after long-term exposure (eradicate *P. vivax/ovale* hypnozoites)

**Tafenoquine:**
- **Dose:** 200mg PO daily × 3 days (loading), then 200mg weekly
- **Timing:** Start **3 days before** (loading), continue **weekly during**, stop **7 days after** leaving endemic area
- **Advantages:** Weekly dosing, short post-travel course
- **Disadvantages:** Requires **G6PD testing**, long half-life (2 weeks), expensive, not widely available

### **Choosing Prophylaxis:**

**Chloroquine-Sensitive Areas:**
- **Chloroquine** (first-line, safe in pregnancy)

**Chloroquine-Resistant Areas (Most Endemic Regions):**
- **Atovaquone-proguanil** (first-line if can afford, best tolerability)
- **Doxycycline** (first-line if cost is issue, avoid sun)
- **Mefloquine** (if weekly dosing preferred, assess psychiatric history first)

**Pregnancy:**
- **Chloroquine** (if chloroquine-sensitive area)
- **Mefloquine** (if chloroquine-resistant area, after 1st trimester)
- **Avoid:** Doxycycline (teratogenic), atovaquone-proguanil (limited safety data), primaquine/tafenoquine (G6PD risk)

**Children:**
- **Atovaquone-proguanil** (>5 kg)
- **Mefloquine** (>5 kg, avoid if seizure history)
- **Chloroquine** (if chloroquine-sensitive)
- **Avoid:** Doxycycline (<8 years, dental staining)

### **Non-Pharmacologic Prevention:**

**Personal Protective Measures:**
- **DEET-containing insect repellent** (20-50%)
- **Permethrin-treated clothing/bed nets**
- **Long sleeves/pants** (dusk-dawn)
- **Air conditioning/screens** (mosquitoes avoid cool, enclosed spaces)

### **Terminal Prophylaxis (*P. vivax/ovale*):**

**Indication:** After prolonged exposure (>6 months) to *P. vivax/ovale* endemic areas
- **Primaquine 30mg (base) PO daily × 14 days** after leaving endemic area
- **OR tafenoquine 300mg PO × 1** (single dose)
- **Eradicates liver hypnozoites** (prevents relapse weeks-months later)
- **Requires G6PD testing** before use

## Key Points

### **Atovaquone-Proguanil = Best Tolerability:**
- **Short post-travel** course (7 days)
- **Well-tolerated** (minimal side effects)
- **Expensive**

### **Doxycycline = Cheapest:**
- **Photosensitivity** (avoid sun, use sunscreen)
- **Long post-travel** course (28 days)
- **Not for pregnancy/children <8**

### **Mefloquine = Weekly, But Neuropsych Side Effects:**
- **Screen for psychiatric history** (contraindicated if depression, anxiety, psychosis, seizures)
- **Start ≥2 weeks before** to assess tolerability

### **Chloroquine = Rare (Resistance):**
- **Only for chloroquine-sensitive areas** (Central America, Caribbean)
- **Safe in pregnancy**

### **Primaquine Requires G6PD Testing:**
- **Hemolysis in G6PD deficiency** (can be fatal)
- **Must test** before prescribing

### **Clinical Pearls:**
- **Chloroquine-resistant areas (most):** Atovaquone-proguanil (best) OR doxycycline (cheap)
- **Chloroquine-sensitive (rare):** Chloroquine
- **Pregnancy:** Mefloquine (after 1st trimester, chloroquine-resistant areas)
- **Terminal prophylaxis (*P. vivax/ovale*):** Primaquine × 14 days (requires G6PD testing)
- **Personal protection:** DEET, permethrin, long sleeves (dusk-dawn)

## Sources

- [CDC: Malaria Prophylaxis (Yellow Book) 2024]
- [WHO: Malaria Prevention 2024]

## Media

N/A
